Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csorgo Z, Dimachkie MM, Griger Z, et al. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med 2022;387(14):1264-78. https://www.ncbi.nlm.nih.gov/pubmed/36198179
Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol 2020;16(12):689-701. https://www.ncbi.nlm.nih.gov/pubmed/33093664
Anh-Tu Hoa S, Hudson M. Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies. Semin Arthritis Rheum 2017;46(4):488-508. https://www.ncbi.nlm.nih.gov/pubmed/27908534
Ashton C, Paramalingam S, Stevenson B, Brusch A, Needham M. Idiopathic inflammatory myopathies: a review. Intern Med J 2021;51(6):845-52. https://www.ncbi.nlm.nih.gov/pubmed/34155760
Ig Governance. Inflammatory myopathies: polymyositis (PM), dermatomyositis (DM) and necrotising autoimmune myopathy (NAM) version 3.2. Criteria for clinical use of immunoglobulin in Australia. Canberra: National Blood Authority. 2020; Accessed Nov 2022. https://www.criteria.blood.gov.au/MedicalCondition/View/2616
Needham M, Mastaglia FL. Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment. Clin Neurophysiol 2016;127(3):1764-73. https://www.ncbi.nlm.nih.gov/pubmed/26778717
